The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2023 | CXCR1/2 and PD-1 inhibition in ctDNA positive and RAS-mutant CRC
Myeloid-derived suppressor cells have been found to increase the risk of metastasis, and activation of the CXCR2 axis via KRAS mutations is a crucial step in this process. Benny Johnson, DO, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of the Phase I/II STOPTRAFFIC-1 trial (NCT04599140) of SX-682, a novel oral small-molecule inhibitor of CXCR1/2 chemokine receptors, with nivolumab in patients with colorectal cancer (CRC). Patients refractory RAS-mutated microsatellite stable (MSS) or circulating tumor DNA (ctDNA) positive CRC were recruited. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
